Issue Archive

In this issue of Blood, Pagel and colleagues compare pretargeted versus conventional radioimmunotherapy in lymphoma models, reporting the superiority of pretargeting and lack of benefit for antibody cocktails versus a single antibody.

In this issue of Blood, Karp and colleagues describe preclinical and clinical effects of the combination of tipifarnib with etoposide. The study represents an admirable example of successful translation of in vitro data to a phase 1 clinical trial.

In this issue of Blood, 2 articles describe the evolution of the PF4/heparin immune response and provide further proof that the HIT immune response is anything but typical.

Blood group antigens can have critical functions beyond the red blood cell. In this issue of Blood, Lund and colleagues demonstrate a role for P^k in HIV entry, providing biologic insight, identifying potential therapeutic target motifs and expanding the intersections of hematology, transfusion medicine, and infectious disease.

Two mechanisms for targeting tumor vasculature are well recognized: antiangiogenesis and vascular disruption. In this issue of Blood, Bieker and colleagues take therapeutic advantage of coagulation and add a third mechanism, vascular infarction, to this group by demonstrating the effect through first-in-man administration of tTF-NGR.